Long non‑coding RNA HOTTIP is able to predict poor prognosis in various neoplasms: A meta‑analysis

  • Authors:
    • Ning Jin
    • Ling‑Yun Yang
    • Zi‑Peng Xu
  • View Affiliations

  • Published online on: June 15, 2017     https://doi.org/10.3892/mco.2017.1293
0

Abstract

HOXA distal transcript antisense RNA (HOTTIP), a critical oncogenic long non‑coding RNA, has been reported to be aberrantly regulated in various cancer types. The present meta‑analysis aimed to investigate HOTTIP as a potential clinical applicable prognostic biomarker in malignant neoplasms. Literature collections were performed by searching the electronic databases, PubMed and Web of Science (up to July 20, 2016). All the relevant searches were conducted to identify the association of HOTTIP with the overall survival (OS) rate. A total of six articles consisting of 508 patients were included in the present meta‑analysis. The results suggested that the overexpression of HOTTIP is closely correlated with poor OS (hazard ratio=2.28; 95% confidence interval=1.71‑3.04; P=0.000). In conclusion, the present meta‑analysis has demonstrated that an increased expression level of HOTTIP is correlated with poor OS in different types of cancer, suggesting that HOTTIP potentially serves as a reliable prognostic biomarker in different types of cancer.

Related Articles

Journal Cover

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Jin, N., Yang, L., & Xu, Z. (1899). Long non‑coding RNA HOTTIP is able to predict poor prognosis in various neoplasms: A meta‑analysis. Molecular and Clinical Oncology, 0, 0-0. https://doi.org/10.3892/mco.2017.1293
MLA
Jin, N., Yang, L., Xu, Z."Long non‑coding RNA HOTTIP is able to predict poor prognosis in various neoplasms: A meta‑analysis". Molecular and Clinical Oncology 0.0 (1899): 0-0.
Chicago
Jin, N., Yang, L., Xu, Z."Long non‑coding RNA HOTTIP is able to predict poor prognosis in various neoplasms: A meta‑analysis". Molecular and Clinical Oncology 0, no. 0 (1899): 0-0. https://doi.org/10.3892/mco.2017.1293